IM-1617 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, IM-1617, to determine its safety and effectiveness for individuals with solid tumor cancers that have spread or cannot be surgically removed. The study consists of two parts: the first identifies a safe dose, and the second evaluates how well that dose combats cancer. It targets individuals with advanced cancer that does not respond to standard treatments or specific types like breast or lung cancer. Participants should have a type of solid tumor cancer that is noncurable and lacks effective treatment options. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects on people.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that IM-1617 is likely to be safe for humans?
Research shows that IM-1617 remains in the early stages of testing, focusing primarily on safety and tolerability. As it is in Phase 1 trials, researchers continue to gather detailed safety information from human participants.
Before human testing, lab and animal studies showed promising results, with some tumors shrinking. However, these early results do not always predict outcomes in humans.
In this Phase 1 trial, the main goal is to assess how well participants tolerate IM-1617 and identify any side effects. Participants will help researchers understand how the drug functions in the body and determine the appropriate dose for future studies.12345Why do researchers think this study treatment might be promising for cancer?
Unlike the standard treatments for cancer, which often include chemotherapy and radiation, IM-1617 is unique because it is administered intravenously and might offer a novel way to target cancer cells. Researchers are excited about IM-1617 because it could represent a new mechanism of action compared to existing therapies. This treatment has the potential to be more effective with fewer side effects, providing a promising new option for patients.
What evidence suggests that IM-1617 might be an effective treatment for solid tumor cancer?
Research has shown that IM-1617 has promising results in early tests. In these studies, a single dose of IM-1617 decreased tumor size in melanoma models, a type of skin cancer. This suggests the drug might effectively shrink tumors. Although these results come from pre-human trials, they provide a strong foundation for studying IM-1617's potential to treat solid tumors in people. In this trial, participants will receive IM-1617 either through dose escalation or as part of a monotherapy dose expansion. The drug uses a special approach to deliver treatment directly to cancer cells.15678
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumor cancers (like colorectal, lung, breast, stomach, or esophageal cancer) that have spread or can't be removed by surgery. Participants must be able to care for themselves most of the time and meet specific health criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Part A: A dose-escalation phase to evaluate the safety and tolerability of IM-1617 to determine the recommended dose for expansion (RDE), evaluate maximum tolerated dose, and maximum achievable dose of IM-1617
Dose Expansion
Part B: An expansion phase to further evaluate the safety and preliminary antitumor activity of IM-1617 monotherapy at the RDE and one or more other dose regimens
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IM-1617
Trial Overview
The study is testing a new drug called IM-1617. In Part A, different doses are given to find the safest amount; in Part B, the chosen dose is tested further for safety and effectiveness against various advanced cancers.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
IM-1617 given into the vein (IV; intravenously)
IM-1617 given into the vein (IV; intravenously)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immunome, Inc.
Lead Sponsor
Citations
A Phase 1 Study of IM-1617 in Participants With Advanced ...
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid ...
IM-1617 (Solid Tumor Antibody Drug Conjugate)
Preclinical in vivo efficacy studies showed tumor regression after a single, clinically relevant dose of IM-1617 in tumor models derived from melanoma ...
Immunome Reports Full Year 2025 Financial Results and ...
Preclinical ADC Pipeline: Immunome expects to submit INDs for IM-1617, IM-1340 and IM-1335 in early, mid, and late-2026, respectively. The ...
EX-99.1
In an exploratory analysis, varegacestat demonstrated a median best change in tumor volume of -83% vs. +11% with placebo, as assessed by blinded independent ...
5.
synapse-patsnap-com.libproxy1.nus.edu.sg
synapse-patsnap-com.libproxy1.nus.edu.sg/drug/184d97cadebd4458b37e1554c8884087IM-1617 - Drug Targets, Indications, Patents
Related. 100 Clinical Results associated with IM-1617. Login to view more data ... Identify the latest clinical trials across global registries. login. or.
Immunome Reports First Quarter 2026 Financial Results ...
IM-1617 is a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporates HC74, Immunome's proprietary TOP1 ...
Immunome Announces Pipeline Advancements, Including ...
Immunome is progressing three novel ADC programs—IM-1617, IM-1340, and IM-1335—for solid tumor indications through preclinical development.
8.
tipranks.com
tipranks.com/news/company-announcements/immunome-expands-oncology-pipeline-with-new-phase-1-im-1617-trialImmunome Expands Oncology Pipeline With New Phase 1 ...
... IM-1617 shows competitive data. Peers in the ADC field have seen sharp moves on early safety and response signals, so even initial readouts ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.